First-line ICIs in renal cell carcinoma

Vincenzo Fiorentino, Pietro Tralongo, Luigi Maria Larocca, Cristina Pizzimenti, Maurizio Martini, Francesco Pierconti

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Treatment of metastatic renal cell carcinoma (mRCC) has radically changed, switching from interferon alfa (IFN-& alpha;) and high-dose interleukin-2 (HD IL-2) to new targeted therapies directed against tumoral neoangiogenesis, the mammalian target of the rapamycin (mTOR) pathway and immune checkpoints. Of note, the inhibition of immune checkpoints restores antitumor immune response, therefore promoting immune-mediated elimination of neoplastic cells. The best example of this targeted treatment is represented by PD-1/PD-L1 inhibition that has become the standard of care in mRCC treatment and has improved mRCC patients' prognoses after failure of other targeted therapies. In this manuscript, we review the main therapeutic protocols adopted for mRCC, based on the use of immune checkpoint inhibitors (ICIs) alone or combined with other drugs.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaHUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume19
DOI
Stato di pubblicazionePubblicato - 2023

Keywords

  • Immune checkpoint inhibition

Fingerprint

Entra nei temi di ricerca di 'First-line ICIs in renal cell carcinoma'. Insieme formano una fingerprint unica.

Cita questo